KMKristy Miskimen

Kristy Miskimen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kristy Miskimen has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Examining the Performance of Polygenic Risk Scores for Alzheimer Disease Within and Across Populations Using k -Fold Cross-Validation

    by Michael D. Osterman, Yeunjoo E. Song, Audrey Lynn, Kristy Miskimen, Nicholas R. Wheeler, Jacquelaine Bartlett, Lindsay A. Farrer, Gerard D. Schellenberg, Eden R. Martin, Margaret A. Pericak-Vance, et al.

    Alzheimer disease (AD) has a complex etiology with a strong genetic component. Despite mounting evidence that genetic risk effect sizes vary by population, most research on the genetics of AD has examined only data sets of individuals with European ancestry. In this study, we investigate the variable performance and transferability of polygenic risk scores (PRSs) by deriving a PRS from analyses of AD for various race and ethnic categories and applying this across groups using a k-fold cross-validation approach. After quality control and application of inclusion criteria, we analyzed 11,254 individuals from the Alzheimer's Disease Sequencing Project Release 3 with 3 predominant self-identified race/ethnicity groups: Hispanic individuals (n = 2,207), non-Hispanic Black individuals (n = 2,437), and non-Hispanic White individuals (n = 6,610). For each group, a 5-fold cross-validation approach was used to perform a genome-wide association study (training) and construct PRS estimates (test). This approach allowed for consideration of within-group and across-group PRS performance. Area under the curve (AUC) was calculated for each race/ethnicity-specific PRS within each cross-validation fold. Various PRS criteria were considered, including rare single-nucleotide polymorphisms and the APOE region in calculation, sex-specific PRSs, and different sample sizes of training and test groups, and their effects were examined through goodness-of-fit metrics in reduced and full models. Across all participant groups, the PRS trained in the same race/ethnicity category as the test group nearly exclusively outperformed the other PRSs with considerable benefit in the Hispanic group. The range of AUCs across iterations was also greater when applying PRSs from other groups. These findings were consistent after inclusion of APOE, sex, and age covariates and through different PRS generation criteria. In this study, we demonstrated the variable performance of AD PRSs within race/ethnicity groups and the weakness in transferability across groups, accounting for different criteria in PRS calculation. This work provided a framework for improving PRS application for AD and highlighted the importance of recruiting diverse populations in genetic studies.


  • Open Access

    AI/ML-Derived Whole-Genome Predictor Prospectively and Clinically Predicts Survival and Response to Treatment in Brain Cancer

    by Sri Priya Ponnapalli, Penelope Miron, Kristy L. S. Miskimen, Kristin A. Waite, Nadiya Sosonkina, Sara E. Coppens, Anthony C. Bryan, Estevan P. Kiernan, Huanming Yang, Jay Bowen, et al.


  • Open Access

    Supplementary Figures 1 - 8, Tables 1 - 3 from Conserved Oncogenic Behavior of the FAM83 Family Regulates MAPK Signaling in Human Cancer

    by Rocky Cipriano, Kristy L.S. Miskimen, Benjamin L. Bryson, Chase R. Foy, Courtney A. Bartel, Mark W. Jackson

    PDF file - 1239KB, S1. Expression of exogenous FAM83B relative to endogenous FAM83B. Western blot of control GFP-expressing HME1 cells and FAM83B-expressing HME1 cells using a FLAG antibody or a FAM83B antibody. S2. Expression of FAM83A, FAM83B and FAM83D in lung cancer subtypes. The samples included normal lung (Norm - 38 samples), squamous cell carcinoma (SCC - 30 samples), Adenocarcinoma (Ad - 33 samples), Adenosquamous carcinoma (AdS - 4 samples), non-small cell carcinoma (NSC - 9 samples), large cell carcinoma (LC - 12 samples), small cell carcinoma (SC - 3 samples). The significant p-values defined as follows, p<0.005 (*) and p<0.05 (#). S3. FAM83 member expression in normal tissues. Real-time PCR analysis was performed for FAM83 members A-E. The relative expression of each FAM83 member is presented from all normal, associated tissues from an Origene TissueScan Cancer Survey Panel. The expression of each FAM83 member in each tissue was normalized to its expression in the adrenal gland, which was set equal to 1. S4. FAM83 member expression in normal tissues. The expression of FAM83A-E were examined in 353 various normal tissues were analyzed on Affymetrix U133 Plus 2.0 microarrays in a study by Roth et al. Neurogenetics. 2006 May,7(2):67-80. S5. FAM83A or FAM83D knock-down impairs MCF7 cell growth. MCF7 cells were infected with lentiviruses encoding a shRNA targeting GFP, FAM83A, or FAM83D. Western and Real Time PCR analysis confirmed the suppression of FAM83A protein (A) and FAM83D mRNA (B). MCF7 cells expressing shRNAs were plated, grown for 8 days, and the cell number was determined (C). S6. Specificity of FAM83 shRNAs. MDA468 cells were infected with lentiviruses expressing shRNAs targeting GFP (shGFP), FAM83A (sh83A2), FAM83B (sh83B2), or FAM83D (sh83D2). Real-time PCR was performed to analyze FAM83A, FAM83B, or FAM83D mRNA levels in the infected cells to confirm the specificity of each shRNA construct. S7. Analysis of RAS activation in FAM83-expressing cells. RAS activation assay was performed according to the procedures recommended by Upstate. Lysates from cells expressing Vector, FAM83A, FAM83B, or FAM83D were precipitated using a glutathione S-transferase (GST) fusion protein containing the RAS-binding domain (RBD) of CRAF (GST-CRAF-RBD) bound to agarose beads, and the bead-associated proteins were analyzed by SDS page electrophoresis followed by immunoblotting using anti-RAS and anti-GST antibodies. S8. Multiple FAM83 members are coordinately overexpressed in cancer. Heatmaps showing relative expression of FAM83A, FAM83B, FAM83C, or FAM83D in the panel of cancer specimens presented in Figure 3. RAN-BP3 and EGFR were examined in Breast and Lung specimens, respectively. The sample sizes for each tissue type are as follows: Ovarian: N=13, C=76. Breast: N=16, C=191. Lung: N=38, C=98. Bladder: N=3, C=18. Table S1. FAM83 member identification by mass spectrometry. Table S2. Relative expression of FAM83 members in HME1 cells. Table S3. Summary of FAM83 member expression in tumor microarray datasets.

  • Open Access

    Preferential preservation of constructional praxis delayed recall compared to word list delayed recall in the Amish

    by Michael B. Prough, Laura J. Caywood, Jason E. Clouse, Sharlene D. Herington, Susan H. Slifer, Daniel A. Dorfsman, Larry D. Adams, Renee A. Laux, Yeunjoo E. Song, Audrey Lynn, et al.

  • Genome‐wide association for protective variants in Alzheimer’s disease in the Midwestern Amish

    by Leighanne R Main, Yeunjoo E. Song, Renee A. Laux, Kristy L. Miskimen, Michael L. Cuccaro, Paula K. Ogrocki, Alan J. Lerner, Jeffery M. Vance, M. Denise Fuzzell, Sarada L. Fuzzell, et al.

  • Open Access

    Search for protective genetic variants in Alzheimer disease in the U.S. Midwestern Amish

    by Leighanne R. Main, Yeunjoo E. Song, Renee A. Laux, Kristy Miskimen, Michael L. Cuccaro, Paula Ogrocki, Alan J. Lerner, Jeffery M. Vance, M. Denise Fuzzell, Sarada L. Fuzzell, et al.

    Background: Most genetic studies on Alzheimer’s disease (AD) have focused on finding risk genes and variants. Taking into account the 30+ loci identified to increase risk of AD, still only around 40‐50% of the estimated heritability of AD is explained. Our goal is to identify genetic variants that delay the onset or protect against the development of AD and to find novel gene interactions or pathways associated with AD.Method: Our study focuses on the Amish communities in Ohio and Indiana due to their homogeneous genetics and environment. Studying genetics in the Amish increases our ability to find rare protective variants for AD that do not exist at a detectable frequency in the general population. Our focus is to identify individuals who are cognitively normal (CN), but at high risk for developing AD (i.e. have an affected sibling). Each of these individuals is retested every two years to assess their cognition status.Results: Using the extensive genealogical data of families in the Amish population, we have generated a large ∼5,000 person, 13‐generation pedigree. As of January 2020, we have ascertained 652 individuals and are examining over 300,000 SNPs that were retained after preliminary QC. Out of the recently adjudicated enrollments, 55 percent are cognitively normal, 33 percent are borderline or cognitively impaired, and the remainder have been sampled and are awaiting a consensus diagnosis. The frequency of the APOE‐e2 allele in our enrollments is at 5%, while the APOE‐e4 allele is at 14%, is lower than the general European population. We are currently using KING and GENESIS software to QC the data since they take into account more relatedness in a population structure, which is needed for working with the Amish. Association and linkage analyses, taking into account the complex pedigree relationships, is ongoing.Conclusion: We are using a founder population to have an increased chance of finding protective genetic variants in AD. We are specifically targeting individuals who are at high risk for developing AD, but seem to be resilient. This is important in discovering novel pathways in which AD functions, which can lead to further functional and pharmaceutical studies.

  • Open Access

    Longitudinal assessment of cognitive decline in the Amish

    by Yeunjoo E. Song, Kristy Miskimen, Renee A. Laux, M. Denise Fuzzell, Sarada L. Fuzzell, Jane L. Sewell, Sherri D. Miller, Larry D. Adams, Laura J. Caywood, Michael Prough, et al.

    Background: The Modified Mini‐Mental State (3MS) is a widely used measure of global cognition. The Old Order Amish are both genetically and environmentally homogeneous, with similar years of formal education across the population. Here, we investigated the longitudinal course of cognitive function as measured by the distribution of 3MS in the Mid‐Western Amish.Method: After extensive QC, the 919 subjects with both baseline 3MS and AD status were analyzed. The change from 1st to 2nd measurement was used as the main longitudinal trait of interest. Mean decline differences in 4 baseline age groups (=90) were assessed. The differences in the average longitudinal decline of 3MS between AD cases and controls was assessed using Kolmogorov‐Smirnov tests and ANCOVA adjusted for age at exam and sibship.Result: The overall baseline mean 3MS score was 89.52 [42, 100] at the mean age of exam 75.52 [60, 99]. The overall annual rate of decline was ‐0.3 [‐5, 5] from 1st to 2nd measurement (n=242) and ‐0.6 [‐2.1, 1.3] from 2nd to 3rd measurement (n = 23). The annual rate of decline was ‐0.96 [‐4, 1.7] in AD cases (n=18), ‐0.01 [‐5, 5] in AD controls (n=180) and ‐1.08 [‐5, 0.7] in an ‘Unclear’ group (n = 44). The most rapid annual decline of the 3MS was in age 80 to 90 group and the decline rate was significant (p‐value=0.004) compared to the lowest age group (<70) overall and in AD cases. In the Unclear group, the rate of decline was greatest in age 70 to 80. However, in the control group, cognition improved, with a 1.29 [‐1, 5] annual increase in age 80 to 90. The age and sibship adjusted differences in decline were significant (p‐value<2e‐10) between AD cases vs. controls as well as between Unclear vs. controls.Conclusion: We explored the changes of 3MS scores over time and demonstrated different patterns of decline by age and AD status in the Amish. Our study is the first in this homogeneous Amish population, providing a better understanding and insight into the cognitive decline examining the change in 3MS over time.

  • Open Access

    Joint linkage and association mapping of preserved cognition in the old‐order Amish

    by Jairo Ramos, James Jaworski, Larry D. Adams, Renee A. Laux, Laura J. Caywood, Michael Prough, Jason E. Clouse, Sharlene D. Herington, Susan H. Slifer, M. Denise Fuzzell, et al.

    Background: Most studies on Alzheimer Disease (AD) have focused on the identification of variants associated with increased risk. The Amish is a genetically homogeneous population ideal to investigate susceptibility genes for complex traits such as AD. This study aims to use family‐based linkage and association approaches to identify genetic variants that protect against the development of cognitive impairment (CI), the central feature of AD.Method: A total of 800 adults from Amish communities in Indiana and Ohio were screened for CI using the 3MS test. Individuals were classified as cognitively normal (CN) if the 3MS score was ≥87 at age 75 and cognitively impaired if < 87 at any age. Samples were genotyped on the Illumina Infinium Global Screening or Expanded Multi‐Ethnic Genotyping Array. Over 7 Million common and rare variants were then imputed using the HRC reference panel. For the linkage analysis 75 nuclear families containing at least two CN individuals were analyzed using Merlin to fit multipoint non‐parametric linkage models and parametric affected‐only (AO) dominant and recessive models using a map of more than 40,000 genotyped markers. The genome‐wide association study (GWAS) of imputed variants utilized the program Genesis to fit a logistic regression model 426 CN to 360 CI, associating each variant with cognitive status while adjusting for sex, pc1, pc2 and relatedness.Result: The top linkage peaks were seen in the parametric multipoint AO dominant model: Chr3 (HLOD = 2.6) ∼3.9 mb region (21.0 mb – 24.9 mb) and Chr11 (HLOD 2.1) ∼6.5 mb (11.0 mb – 17.5 mb). In the GWAS analysis, no variants reached genome wide significance (5 × 10−8). However, using a lower significance threshold for regional association under a linkage peak (p < 10−5), 7 associated variants were identified in two regions under the Chr11 peak.Conclusion: We identified a 6.5 mb area of interest on chromosome 11 associated with preserved cognitive function in Amish adults over age 75, which is near OTOG a previously reported gene associated with AD. This region merits further investigation for functional variants that might slow or prevent the development of cognitive impairment in older adults.

  • Open Access

    P3‐140: PROTECTIVE EFFECT OF EDUCATION ON COGNITIVE FUNCTION IN THE OLD ORDER AMISH

    by Jairo Ramos, Laura J. Caywood, Michael Prough, M. Denise Fuzzell, Sarada Fuzzell, Kristy Miskimen, Patrice L. Whitehead, Larry D. Adams, Renee Laux, Yeunjoo Song, et al.

  • Open Access

    P3‐135: PROTECTIVE GENETIC VARIANTS IN THE MIDWESTERN AMISH

    by Leighanne R. Main, Michelle C. Disher, Yeunjoo Song, Renee Laux, Kristy Miskimen, Michael L. Cuccaro, Paula Ogrocki, Alan J. Lerner, Jeffery M. Vance, M Denise Fuzzell, et al.